A recent double-blind placebo controlled, 3-arm multicentre trial, assessed the impact of individualised homeopathy on stage 4 non-small cell lung cancer patients, when added to conventional treatment. The study, involving 150 patients, found that add-on homeopathy improved quality of life and prolonged survival time, indicating that an integrated approach should be considered for optimal outcomes.

This study builds on the findings of earlier research on this topic, presented by Prof Michael Frass at HRI Malta 2017.